tiprankstipranks
Trending News
More News >
Premier Anti-Aging Co., Ltd. (JP:4934)
:4934
Japanese Market
Advertisement

Premier Anti-Aging Co., Ltd. (4934) AI Stock Analysis

Compare
0 Followers

Top Page

JP:4934

Premier Anti-Aging Co., Ltd.

(4934)

Rating:57Neutral
Price Target:
¥933.00
▲(1.52%Upside)
The overall stock score reflects the company's financial struggles, particularly in revenue and profitability, offset by a reasonable valuation. Technical indicators are mixed, showing some bearish momentum, while a low P/E ratio suggests potential undervaluation.

Premier Anti-Aging Co., Ltd. (4934) vs. iShares MSCI Japan ETF (EWJ)

Premier Anti-Aging Co., Ltd. Business Overview & Revenue Model

Company DescriptionPremier Anti-Aging Co., Ltd. (4934) is a Japanese company specializing in the development and sale of skincare and beauty products, primarily focused on anti-aging solutions. The company operates in the personal care sector, offering a range of products that target aging concerns, leveraging advanced technologies and ingredients to cater to the needs of consumers seeking youthful and radiant skin.
How the Company Makes MoneyPremier Anti-Aging Co., Ltd. generates revenue through the direct sale of its skincare and beauty products. The company's primary revenue streams include online sales via its e-commerce platforms and physical sales through retail partners. Premier Anti-Aging Co., Ltd. benefits from a strong brand presence and effective marketing strategies, which help in capturing a significant share of the anti-aging market. Strategic partnerships and collaborations with retailers and distributors also play a crucial role in expanding its reach and driving sales. Additionally, the company invests in research and development to continuously innovate and enhance its product offerings, ensuring customer satisfaction and loyalty.

Premier Anti-Aging Co., Ltd. Financial Statement Overview

Summary
Premier Anti-Aging Co., Ltd. is experiencing financial challenges with declining revenue and profitability. While the balance sheet remains relatively stable, cash flow issues are concerning and need to be addressed for improved financial health.
Income Statement
40
Negative
The income statement reveals a concerning trend of declining revenue and profitability. The gross profit margin has remained high, but net profit margin has been negative for recent years, with 2024 showing significant net losses. Revenue has decreased consistently since 2022, indicating problematic revenue growth and operational challenges.
Balance Sheet
60
Neutral
The balance sheet is relatively stable, with a steady stockholders' equity and manageable debt levels. The debt-to-equity ratio remains reasonable, and the equity ratio is healthy, indicating a solid capital structure. However, declining total assets could pose a risk if the trend continues.
Cash Flow
50
Neutral
Cash flow analysis shows fluctuating free cash flow, with recent periods experiencing negative figures. Operating cash flow has been positive, but the lack of consistent free cash flow growth is a concern. The company needs to improve cash flow management to ensure financial stability.
BreakdownTTMSep 2024Sep 2023Sep 2022Sep 2021Sep 2020
Income Statement
Total Revenue19.32B20.36B26.40B33.91B32.81B20.51B
Gross Profit15.33B16.10B19.24B26.63B26.43B16.48B
EBITDA16.50M-627.00M-432.24M2.67B4.71B1.68B
Net Income-1.03B-1.48B-733.97M1.42B2.79B1.14B
Balance Sheet
Total Assets11.16B11.00B12.14B12.30B13.07B6.85B
Cash, Cash Equivalents and Short-Term Investments5.06B4.76B4.67B2.97B6.06B1.90B
Total Debt2.06B2.44B2.26B1.41B911.41M1.99B
Total Liabilities4.63B4.88B4.53B3.95B6.17B5.40B
Stockholders Equity6.54B6.12B7.61B8.35B6.90B1.45B
Cash Flow
Free Cash Flow0.00-395.00M1.64B-3.53B2.68B196.34M
Operating Cash Flow0.00425.00M2.42B-3.32B2.75B338.23M
Investing Cash Flow0.00-540.00M-900.97M-297.68M-180.83M-135.76M
Financing Cash Flow0.00183.00M179.77M501.62M1.58B979.68M

Premier Anti-Aging Co., Ltd. Technical Analysis

Technical Analysis Sentiment
Positive
Last Price919.00
Price Trends
50DMA
909.82
Positive
100DMA
873.09
Positive
200DMA
820.35
Positive
Market Momentum
MACD
1.12
Negative
RSI
56.39
Neutral
STOCH
73.34
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4934, the sentiment is Positive. The current price of 919 is above the 20-day moving average (MA) of 903.35, above the 50-day MA of 909.82, and above the 200-day MA of 820.35, indicating a bullish trend. The MACD of 1.12 indicates Negative momentum. The RSI at 56.39 is Neutral, neither overbought nor oversold. The STOCH value of 73.34 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:4934.

Premier Anti-Aging Co., Ltd. Peers Comparison

Overall Rating
UnderperformOutperform
Sector (65)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
69
Neutral
¥11.79B57.48
3.07%4.75%-83.63%
65
Neutral
$27.23B15.60-4.43%2.56%1.05%4.97%
63
Neutral
¥22.88B10,315.80
0.24%16.15%19.02%
61
Neutral
¥6.23B10.81
2.43%-2.13%
57
Neutral
¥6.11B158.30
1.58%-9.81%
57
Neutral
¥8.01B10.99
-17.95%
45
Neutral
¥4.93B36.16
1.74%0.10%-239.09%
* Consumer Defensive Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
JP:4934
Premier Anti-Aging Co., Ltd.
919.00
25.00
2.80%
JP:4925
HABA Laboratories, Inc.
1,648.00
-318.66
-16.20%
JP:4926
C'BON COSMETICS Co., Ltd.
1,151.00
-225.64
-16.39%
JP:4929
ADJUVANT HOLDINGS CO., LTD.
760.00
-97.44
-11.36%
JP:4935
Liberta Co., Ltd.
3,800.00
2,677.84
238.63%
JP:4936
AXXZIA, Inc.
489.00
-414.75
-45.89%

Premier Anti-Aging Co., Ltd. Corporate Events

Premier Anti-Aging Revises Earnings Forecast Amid Mixed Business Performance
Jun 12, 2025

Premier Anti-Aging Co., Ltd. has revised its full-year consolidated earnings forecast for the fiscal year ending July 31, 2025, due to mixed performance across its business segments. While the recovery business through subsidiary Venex Co., Ltd. showed strong sales, the anti-aging segment underperformed, leading to an overall reduction in expected net sales. Despite this, operating profit exceeded expectations due to reduced advertising expenses and effective cost management. The company plans to invest in marketing for its renewed ‘DUO’ brand and new ‘Lalaskin’ skincare line, while remaining cautious about the challenging business environment, particularly in the Chinese market.

Premier Anti-Aging Reports Financial Results and Revises Forecasts
Jun 12, 2025

Premier Anti-Aging Co., Ltd. reported a decrease in net sales and operating profits for the first nine months of the fiscal year ending July 31, 2025, compared to the previous year. Despite the decline in sales, the company achieved a profit attributable to owners of the parent, indicating a recovery from the previous year’s losses. The company has revised its earnings forecasts for the full fiscal year, suggesting a cautious yet optimistic outlook for future performance.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jul 23, 2025